We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+59.56%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$2.68B
AUM Growth
+$655M
Cap. Flow
+$121M
Cap. Flow %
4.53%
Top 10 Hldgs %
72.14%
Holding
35
New
8
Increased
6
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$92.6M
2
OCUL icon
Ocular Therapeutix
OCUL
+$28.9M
3
RLMD icon
Relmada Therapeutics
RLMD
+$22.9M
4
TENX icon
Tenax Therapeutics
TENX
+$22.7M
5
ANL
Adlai Nortye
ANL
+$21.5M

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$41.6M
2
UPB
Upstream Bio Inc
UPB
+$31.7M
3
CTMX icon
CytomX Therapeutics
CTMX
+$28.3M
4
ERAS icon
Erasca
ERAS
+$17.4M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
26
Cullinan Oncology
CGEM
$1.08B
$19.6M 0.73%
1,379,965
– –
HELP
27
Cybin Inc
HELP
$485M
$18.5M 0.69%
3,851,654
+11,404
+0.3% +$73.8K
SRZN icon
28
Surrozen
SRZN
$252M
$18.4M 0.69%
632,931
– –
SEPN
29
Septerna Inc
SEPN
$1.54B
$12.2M 0.45%
506,056
-104,752
-17% -$2.75M
KRRO icon
30
Korro Bio
KRRO
$169M
$11.4M 0.43%
+1,009,500
New +$11.1M
ANRO icon
31
Alto Neuroscience
ANRO
$1.06B
$11.2M 0.42%
+500,000
New +$9.27M
ARTV
32
Artiva Biotherapeutics
ARTV
$487M
$10.4M 0.39%
1,609,569
– –
XFOR icon
33
X4 Pharmaceuticals
XFOR
$348M
$1.37M 0.05%
+330,525
New +$1.24M
CASI
34
DELISTED
CASI Pharmaceuticals
CASI
– –
-987,259
Closed -$839K
UPB
35
Upstream Bio Inc
UPB
$359M
– –
-1,169,298
Closed -$31.7M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.66B AUM 14.89% 1-Year Est. Return
TPSF
Texas Permanent School Fund Austin, Texas $2.7B AUM 6.73% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return

VR Adviser's Q1 2026 Portfolio in Review

As of Q1 2026, VR Adviser held 35 positions worth $2.68B, up 32% from $2.02B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

VR Adviser deployed $121M of net new capital in Q1 2026, opening 8 new positions and adding to 6 existing holdings. Its largest new stake was Damora Therapeutics, Inc. Ordinary Shares: 3,603,595 shares worth $93.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Enliven Therapeutics, an estimated $41.6M trimmed.

  • VR Adviser's largest Q1 2026 buy was Damora Therapeutics, Inc. Ordinary Shares: 3,603,595 shares worth $93.3M.
  • VR Adviser added most to Ocular Therapeutix in Q1 2026, an estimated $28.9M increase.
  • VR Adviser's biggest Q1 2026 reduction was Enliven Therapeutics, cutting an estimated $41.6M.
  • VR Adviser fully exited Upstream Bio Inc in Q1 2026, selling an estimated $31.7M.
  • VR Adviser's ten largest holdings make up 72% of its $2.68B portfolio in Q1 2026.
  • VR Adviser opened 8 new positions and closed 2 in Q1 2026.
  • VR Adviser's portfolio value rose 32% quarter-over-quarter to $2.68B.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.